Product news

AstraZeneca submitted applications in the European Union for once-daily Seroquel XR (quetiapine fumarate), seeking approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. This follows two supplemental new drug applications to the FDA announced in January, for the same indications.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel